---
title: "Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment | NXL Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283677199.md"
description: "Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment | NXL Stock News"
datetime: "2026-04-22T05:35:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283677199.md)
  - [en](https://longbridge.com/en/news/283677199.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283677199.md)
---

# Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment | NXL Stock News

Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment | NXL Stock News

### Related Stocks

- [NXL.US](https://longbridge.com/en/quote/NXL.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [LABD.US](https://longbridge.com/en/quote/LABD.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [NXLIW.US](https://longbridge.com/en/quote/NXLIW.US.md)

## Related News & Research

- [08:00 ETAvance Clinical Receives Frost & Sullivan's 2026 Global Company of the Year Recognition for Excellence in Biotech CRO Leadership](https://longbridge.com/en/news/286094661.md)
- [Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call](https://longbridge.com/en/news/286422585.md)
- [GRI Bio Highlights Promising Phase 2a IPF Data, Outlook](https://longbridge.com/en/news/286422240.md)
- [Regenxbio's muscle disorder therapy meets main goal in late-stage study](https://longbridge.com/en/news/286406339.md)
- [BUZZ-Dexcom to add two directors in deal with activist Elliott; shares up](https://longbridge.com/en/news/286465778.md)